New treatments using engineered microRNAs for lung cancer
Novel bioengineered microRNA therapeutics for lung cancer
This study is exploring new treatments for lung cancer, especially non-small cell lung cancer, by using special molecules called microRNAs that can help control how cancer cells grow and spread, aiming to offer patients a more effective way to fight their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10977497 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for lung cancer, particularly non-small cell lung cancer (NSCLC), by utilizing bioengineered microRNAs. These microRNAs are natural molecules that can regulate cancer cell processes such as growth and invasion. The approach involves restoring the function of tumor-suppressive microRNAs that are often lost in cancer cells, using a patented technology that allows for the production of these molecules in a way that mimics natural processes in the body. Patients may benefit from a more effective treatment option that targets the underlying mechanisms of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer (NSCLC).
Not a fit: Patients with other types of lung cancer or those who do not have lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with lung cancer.
How similar studies have performed: Other research has shown promise in using engineered microRNAs for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Yu, Aiming — University of California at Davis
- Study coordinator: Yu, Aiming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.